Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SU-014813 in Metastatic Breast Cancer
NCT00322517Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of SU014813 in breast cancer, sponsored by Pfizer. Primary endpoint: Objective Response Rate at 24 weeks. Started Apr 2006; status: completed.
02
Drugs
SU014813
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00322517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322517.